Wind, A. http://orcid.org/0000-0002-9368-2519
Hartman, E. D.
Van Eekeren, R. R. J. P.
Wijn, R. P. W. F.
Halámková, J.
Mattson, J.
Siesling, S.
van Harten, W. H.
Funding for this research was provided by:
Novartis
Article History
Received: 8 July 2020
Accepted: 21 February 2021
First Online: 6 March 2021
Declarations
:
: According to local regulations, we obtained ethical review approval form every center in the second (involvement) study (see Wind et al. for information on the first study [CitationRef removed]). For the Netherlands this study was reviewed and approved by the Institutional Review Board (MREC) of the Radboud University (2019–5406). For Finland ethics approval was waived by the Institutional Review Board of HUS. For the Czech Republic ethical approval was obtained from the Institutional Review Board of MMCI (2019/1829/MOU).Patient consented to participate through the opt-out method. Information about the purpose of the study and the process was given after which patients were explained that if they did not wish to complete the questionnaire, they could mark the opt-out box and return the page. Whether or not patients participated in the study, had no influence on further treatment or any other consequences.
: Not applicable.
: The authors declare that they have no competing interests.